[Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor]

Nihon Rinsho. 1991 Sep;49(9):2149-54.
[Article in Japanese]
No abstract available

MeSH terms

  • Arterial Occlusive Diseases / drug therapy*
  • Arterial Occlusive Diseases / metabolism
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Chronic Disease
  • Epoprostenol / biosynthesis
  • Fatty Acids, Monounsaturated / pharmacology
  • Fatty Acids, Monounsaturated / therapeutic use
  • Humans
  • Methacrylates / pharmacology
  • Methacrylates / therapeutic use
  • Polydeoxyribonucleotides / pharmacology
  • Polydeoxyribonucleotides / therapeutic use
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Thromboxane A2 / analogs & derivatives
  • Thromboxane A2 / biosynthesis
  • Thromboxane A2 / pharmacology
  • Thromboxane A2 / therapeutic use
  • Thromboxane-A Synthase / antagonists & inhibitors*

Substances

  • Fatty Acids, Monounsaturated
  • Methacrylates
  • Polydeoxyribonucleotides
  • Pyridines
  • defibrotide
  • Thromboxane A2
  • ONO 3708
  • Epoprostenol
  • Thromboxane-A Synthase
  • isbogrel
  • ozagrel
  • Aspirin